Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03483103
Other study ID # 017006
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 27, 2018
Est. completion date December 1, 2022

Study information

Verified date November 2023
Source Juno Therapeutics, a Subsidiary of Celgene
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance status, and/or comorbidities). Subjects will receive treatment with lisocabtagene maraleucel and will be followed for 2 years for safety, pharmacokinetics and biomarkers, disease status, quality of life, and survival.


Recruitment information / eligibility

Status Completed
Enrollment 74
Est. completion date December 1, 2022
Est. primary completion date September 24, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Confirmation of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma of the following histology at relapse: diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS; de novo or transformed follicular lymphoma [tFL]), high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (double/triple hit lymphoma [DHL/THL]), and follicular lymphoma Grade 3B per WHO 2016 classification - Previous treatment must include treatment with a single line of chemoimmunotherapy containing an anthracycline and a CD20-targeted agent - Subjects must be deemed ineligible for both high-dose chemotherapy and hematopoietic stem cell transplant (based on age, performance status and/or comorbidities) while also having adequate organ function for CAR T cell treatment. - Positron emission tomography (PET)-positive disease - Histological confirmation of diagnosis at last relapse. Enough tumor material must be available for central confirmation of diagnosis, otherwise a new tumor biopsy is mandated. - ECOG performance status of 0, or 1, or 2 - Adequate vascular access for leukapheresis procedure (either peripheral line or surgically-placed line) - Subjects must agree to use appropriate contraception - Subjects must agree to not donate blood, organs, semen, and egg cells for usage in other individuals for at least 1 year following lymphodepleting chemotherapy Exclusion Criteria: - Subjects with central nervous system (CNS)-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study) - History of another primary malignancy that has not been in remission for at least 2 years. - Previous treatment with CD19-targeted therapy, with the exception of prior lisocabtagene maraleucel treatment in this protocol for subjects receiving retreatment - Active hepatitis B or hepatitis C infection at the time of screening - History of or active human immunodeficiency virus (HIV) infection at the time of screening - Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis or lisocabtagene maraleucel administration - History of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association, cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease - History or presence of clinically relevant CNS pathology - Pregnant or nursing women - Subject does not meet protocol-specified washout periods for prior treatments - Prior hematopoietic stem cell transplant - Progressive vascular tumor invasion, thrombosis, or embolism - Venous thrombosis or embolism not managed on stable regimen of anticoagulation - Uncontrolled medical, psychological, familial, sociological, or geographical conditions

Study Design


Intervention

Biological:
lisocabtagene maraleucel
lisocabtagene maraleucel will be administered as a single dose intravenous (IV) injection

Locations

Country Name City State
United States New York Oncology Hematology - Albany Cancer Center Albany New York
United States New York Oncology Hematology P.C. Albany New York
United States Local Institution - 0019 Atlanta Georgia
United States The Blood and Marrow Transplant Group of Georgia Atlanta Georgia
United States UNC School of Medicine Atlanta Georgia
United States Johns Hopkins Oncology Center Bunting Blaustein Building Baltimore Maryland
United States Local Institution - 0009 Baltimore Maryland
United States The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland
United States Levine Cancer Institute Charlotte North Carolina
United States Local Institution - 0021 Charlotte North Carolina
United States Local Institution - 0003 Chicago Illinois
United States Local Institution - 0016 Chicago Illinois
United States Northwestern University Chicago Illinois
United States Northwestern University Feinberg School of Medicine Chicago Illinois
United States University of Chicago Chicago Illinois
United States University of Chicago Comprehensive Cancer Center Chicago Illinois
United States Local Institution - 0039 Cincinnati Ohio
United States Oncology Hematology Care Cincinnati Ohio
United States Oncology Hematology Care, Inc. Cincinnati Ohio
United States Local Institution - 0083 Dallas Texas
United States UNC School of Medicine Dallas Texas
United States Local Institution - 0052 East Brunswick New Jersey
United States Regional Cancer Care Associates East Brunswick New Jersey
United States UNC School of Medicine East Brunswick New Jersey
United States Banner MD Anderson Cancer Center Gilbert Arizona
United States Local Institution - 0043 Gilbert Arizona
United States Greenville Health System Greenville South Carolina
United States Greenville Health System - Cancer Institute - Faris Road Greenville South Carolina
United States Local Institution - 0037 Greenville South Carolina
United States Scripps Clinic La Jolla California
United States Local Institution - 0046 Lexington Kentucky
United States University of Kentucky Lexington Kentucky
United States University of Kentucky/Markey Cancer Center Lexington Kentucky
United States UNC School of Medicine Los Angeles California
United States University of California Los Angeles Los Angeles California
United States Local Institution - 0064 Louisville Kentucky
United States Norton Cancer Institute - Brownsboro Louisville Kentucky
United States UNC School of Medicine Louisville Kentucky
United States Local Institution - 0055 Milwaukee Wisconsin
United States Medical College of Wisconsin, Froedtert Hospital Milwaukee Wisconsin
United States UNC School of Medicine Milwaukee Wisconsin
United States Local Institution - 0029 Pittsburgh Pennsylvania
United States University of Pittsburgh Medical Center Hillman Cancer Center Pittsburgh Pennsylvania
United States Local Institution - 0051 Portland Oregon
United States Providence Cancer Center/Earle A. Chiles Res. Inst. Portland Oregon
United States Providence Portland Medical Center Portland Oregon
United States Local Institution - 0090 Rochester New York
United States University of Rochester Cancer Center Rochester New York
United States University of Rochester Medical Center Rochester New York
United States Sutter Hematology and Oncology Sacramento California
United States Sutter Medical Center Sacramento California
United States Intermountain Healthcare - LDS Hospital Salt Lake City Utah
United States Intermountain Healthcare - LDS Hospital Blood and Marrow Transplant Salt Lake City Utah
United States Local Institution - 0074 Salt Lake City Utah
United States Local Institution - 0092 Stanford California
United States Stanford Cancer Center Stanford California
United States Stanford Cancer Genetics Clinic Stanford California
United States Northwest Medical Specialties Tacoma Washington
United States UNC School of Medicine Tacoma Washington

Sponsors (1)

Lead Sponsor Collaborator
Juno Therapeutics, a Subsidiary of Celgene

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Response Rate (ORR) Overall response rate is the percent of participants with a best overall response (BOR) of either complete response (CR) or partial reasons (PR) based on the Independent Review Committee (IRC) assessment recorded from the time of JCAR017 treatment until disease progression, end of study, the start of another anticancer therapy or JCAR017 retreatment.
CR = Score 1, 2, or 3 with or without a residual mass on the positron emission tomography 5-point scale (PET 5PS). A score of 3 in many patients indicates a good prognosis with standard treatment.
PR = Score 4 or 5b with reduced uptake compared with baseline and residual mass(es) of any size.
PET 5PS = 1- no uptake above background; 2- uptake = mediastinum; 3- uptake > mediastinum but = liver; 4- uptake moderately > liver; 5- uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
From first dose to disease progression, end of study, the start of another anticancer therapy, or hematopoietic stem cell transplantation (up to approximately 24 months)
Secondary Number of Participants With Any Treatment-Emergent Adverse Events (TEAEs) A TEAE was defined as an adverse event that started any time from initiation of product administration through and including 90 days following product administration. AEs that occurred after the initiation of subsequent anticancer therapy or product retreatment were not considered as product TEAE. AEs are graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (Version 4.03) (NCI CTCAE) guidelines where Grade 3= Severe, Grade 4= Life-threatening, and 5 = Death. From first dose to 90 days following first dose (up to approximately 90 days)
Secondary Change From Baseline of Hematology Laboratory Results: Hemoglobin Change from baseline in Hematology laboratory analysis. Includes Hemoglobin. Baseline is the last observation collected prior to or on the date of product infusion. Baseline and Day 29
Secondary Change From Baseline of Hematology Laboratory Results: Leukocytes, Lymphocytes, Neutrophils, Platelets Change from baseline in Hematology laboratory analysis. Includes Leukocytes, Lymphocytes, Neutrophils, and Platelets. Baseline is the last observation collected prior to or on the date of product infusion. Baseline and Day 29
Secondary Change From Baseline of Chemistry Laboratory Results: Albumin Change from baseline in Chemistry laboratory analysis. Includes Albumin. Baseline is the last observation collected prior to or on the date of product infusion. Baseline and Day 29
Secondary Change From Baseline of Chemistry Laboratory Results: Alanine Aminotransferase, Aspartate Aminotransferase, Lactate Dehydrogenase Change from baseline in Chemistry laboratory analysis. Includes Alanine Aminotransferase, Aspartate Aminotransferase, and Lactate Dehydrogenase. Baseline is the last observation collected prior to or on the date of product infusion. Baseline and Day 29
Secondary Change From Baseline of Chemistry Laboratory Results: Bilirubin, Creatinine, Direct Bilirubin, Urate Change from baseline in Chemistry laboratory analysis. Includes Bilirubin, Creatinine, Direct Bilirubin, and Urate. Baseline is the last observation collected prior to or on the date of product infusion. Baseline and Day 29
Secondary Change From Baseline of Chemistry Laboratory Results: Calcium Corrected, Magnesium, Phosphate, Potassium, Sodium Change from baseline in Chemistry laboratory analysis. Includes Calcium Corrected, Magnesium, Phosphate, Potassium, and Sodium. Baseline is the last observation collected prior to or on the date of product infusion. Baseline and Day 29
Secondary Complete Response (CR) Rate Complete response rate (CRR) was defined as the percent of participants with a best overall response (BOR) of complete response (CR) based on the Independent Review Committee (IRC) assessment recorded from the time of JCAR017 treatment until disease progression, end of study, the start of another anticancer therapy or JCAR017 retreatment.
CR = Score 1, 2, or 3 with or without a residual mass on the positron emission tomography 5-point scale (PET 5PS). A score of 3 in many patients indicates a good prognosis with standard treatment.
PET 5PS = 1- no uptake above background; 2- uptake = mediastinum; 3- uptake > mediastinum but = liver; 4- uptake moderately > liver; 5- uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
From first dose to disease progression, end of study, the start of another anticancer therapy, or hematopoietic stem cell transplant (up to approximately 24 months)
Secondary Duration of Response (DOR) Duration of response (DOR) is defined as the time from first complete response(CR) or partial response (PR) to progressive disease (PD) or death, whichever occurred first.
CR = Score 1, 2, or 3 on the positron emission tomography 5-point scale (PET 5PS). A score of 3 indicates a good prognosis with standard treatment.
PR = Score 4 or 5b with reduced uptake compared with baseline and residual mass(es) of any size.
PD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment.
PET 5PS = 1-no uptake above background; 2-uptake = mediastinum; 3-uptake > mediastinum but = liver; 4-uptake moderately > liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
From first dose to up to approximately 24 months
Secondary Duration of Response (DOR) in Participants With Complete Response (CR) DOR for participants with a best overall response of CR was defined as the time from documentation of first response (or CR) to progressive disease (PD) or death, whichever occurred first. The first documentation of CR/PR is the latest of all dates of required measurements to establish the response. The progression date is the earliest date of all assessments that led to a response assessment of PD.
CR = Score 1, 2, or 3 on the positron emission tomography 5-point scale (PET 5PS). A score of 3 indicates a good prognosis with standard treatment.
PD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment.
PET 5PS = 1-no uptake above background; 2-uptake = mediastinum; 3-uptake > mediastinum but = liver; 4-uptake moderately > liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
From first dose to up to approximately 24 months
Secondary Progression-Free Survival (PFS) PFS is defined as the time from JCAR017 infusion to progressive disease (PD) or death. Kaplan-Meier (KM) methodology will be used to analyze PFS.
PD = Score 4 or 5b on the positron emission tomography 5-point scale (PET 5PS) with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment.
PET 5PS = 1- no uptake above background; 2- uptake = mediastinum; 3- uptake > mediastinum but = liver; 4- uptake moderately > liver; 5- uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
From first dose to progressive disease (PD) or death (up to approximately 24 months)
Secondary Event-Free Survival (EFS) EFS is defined as the time from JCAR017 infusion to the earliest of the following events: death from any cause, progressive disease (PD), or starting a new anticancer therapy. Kaplan-Meier (KM) methodology will be used to analyze EFS.
PD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment.
PET 5PS = 1-no uptake above background; 2-uptake = mediastinum; 3-uptake > mediastinum but = liver; 4-uptake moderately > liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
From first dose to death from any cause, progressive disease (PD), or starting a new anticancer therapy (up to approximately 24 months)
Secondary Overall Survival (OS) OS is defined as the time from JCAR017 infusion to the date of death. Kaplan-Meier (KM) methodology will be used to analyze OS. From first dose to date of death (up to approximately 24 months)
Secondary PK Parameters of JCAR017 in Blood as Assessed by qPCR: Cmax Pharmacokinetic (PK) analyses were based on quantitative polymerase chain reaction (qPCR).
Cmax = Maximum observed blood concentration.
From first dose to up to 24 months
Secondary PK Parameters of JCAR017 in Blood as Assessed by qPCR: Tmax Pharmacokinetic (PK) analyses were based on quantitative polymerase chain reaction (qPCR). Tmax = Time of maximum observed blood concentration. From first dose to up to 24 months
Secondary PK Parameters of JCAR017 in Blood as Assessed by qPCR: AUC (0-28) Pharmacokinetic (PK) analyses were based on quantitative polymerase chain reaction (qPCR). AUC (0-28) = Area under the curve for concentration. From first dose to up to 24 months
Secondary Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Fatigue Subscale Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire.
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.
All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL.
Symptom scale/item higher score represents a high level of symptomatic problem.
Baseline and Day 29
Secondary Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Physical Functioning Subscale Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire.
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.
All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL.
Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
Baseline and Day 29
Secondary Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Cognitive Functioning Subscale Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire.
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.
All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL.
Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
Baseline and Day 29
Secondary Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Global Health/QoL Subscale Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire.
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.
All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL.
Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
Baseline and Day 29
Secondary Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Role Functioning Subscale Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire.
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.
All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL.
Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
Baseline and Day 29
Secondary Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Emotional Functioning Subscale Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire.
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.
All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL.
Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
Baseline and Day 29
Secondary Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Social Functioning Subscale Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire.
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.
All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL.
Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
Baseline and Day 29
Secondary Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Pain Subscale Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire.
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.
All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL.
Symptom scale/item higher score represents a high level of symptomatic problem.
Baseline and Day 29
Secondary Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Nausea/Vomiting Subscale Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire.
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.
All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL.
Symptom scale/item higher score represents a high level of symptomatic problem.
Baseline and Day 29
Secondary Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Constipation Subscale Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire.
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.
All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL.
Symptom scale/item higher score represents a high level of symptomatic problem.
Baseline and Day 29
Secondary Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Diarrhea Subscale Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire.
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.
All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL.
Symptom scale/item higher score represents a high level of symptomatic problem.
Baseline and Day 29
Secondary Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Insomnia Subscale Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire.
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.
All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL.
Symptom scale/item higher score represents a high level of symptomatic problem.
Baseline and Day 29
Secondary Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Dyspnea Subscale Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire.
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.
All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL.
Symptom scale/item higher score represents a high level of symptomatic problem.
Baseline and Day 29
Secondary Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Appetite Loss Subscale Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire.
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.
All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL.
Symptom scale/item higher score represents a high level of symptomatic problem.
Baseline and Day 29
Secondary Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Financial Difficulties Subscale Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire.
The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.
All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL.
Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
Baseline and Day 29
Secondary Health-Related Quality of Life (HRQoL) Assessed by the FACT-Lym Subscale The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) consists of the FACT-General scale and a 15-item lymphoma-specific additional concerns subscale (LYM). This scale addresses symptoms and functional limitations that are important to lymphoma patients. The LYM items are scored on a 0 ("Not at all") to 4 ("Very much") response scale. Items are aggregated to a single score on a 0-60 scale. Baseline and Day 29
Secondary Health-Related Quality of Life (HRQoL) Assessed by the EuroQol Instrument EQ-5D-5L The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. These health states are converted to a single index value using the crosswalk method to the EQ-5D-3L value set from the United Kingdom (UK). The EQ-5D-5L health states ranged from -.594 for the worst (55555) to 1 for the best (11111) for UK value set with an optimal health state is assigned a score of 1.00, death is assigned a score of 0.00 and negative values representing values as worse than dead. A change of .08 is considered to be a clinically meaningful change in health utility. Baseline and Day 29
Secondary Numbers of Intensive Care Unit (ICU) Inpatient Days The numbers of ICU inpatient days. From first dose after JCAR017 infusion to up to approximately 24 months
Secondary Numbers of Non-intensive Care Unit (ICU) Inpatient Days Number of non-ICU inpatient days. From first dose after JCAR017 infusion to up to approximately 24 months
Secondary The Number of Participants That Were Hospitalized For Adverse Events, Prophylaxis, Other Length of hospitalization stay was reported for up to 24 months post liso-cel infusion. Reasons for hospitalization include adverse events, prophylaxis, and other. Adverse events were reported for up to 90 days post liso-cel infusion. From first dose after JCAR017 infusion to up to approximately 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT03484702 - Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma Phase 2
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Completed NCT06190457 - Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
Completed NCT02369016 - Phase III Copanlisib in Rituximab-refractory iNHL Phase 3
Recruiting NCT01676805 - Tissue Collection for Studies of Lymph Cancer
Terminated NCT00916045 - Pilot Study of Unrelated Cord Blood Transplantation Phase 2
Withdrawn NCT00538096 - A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma Phase 1
Terminated NCT00529503 - A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL Phase 2
Completed NCT00534989 - Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT N/A
Withdrawn NCT00319332 - A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen Phase 3
Completed NCT00156013 - Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) Phase 1/Phase 2
Completed NCT00322842 - Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients Phase 2
Completed NCT00141297 - A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer Phase 1
Completed NCT02509039 - A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Phase 1
Completed NCT01573000 - A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL) Phase 2
Completed NCT00268203 - Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma Phase 2
Completed NCT03289182 - An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)